These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32920717)

  • 1. Adding Thiopurine After Loss of Response to Infliximab Versus Early Combination in Treating Crohn's Disease: A Retrospective Study.
    Zeze K; Hirano A; Torisu T; Esaki M; Moriyama T; Umeno J; Kawasaki K; Fujioka S; Fuyuno Y; Matsuno Y; Kitazono T
    Dig Dis Sci; 2021 Sep; 66(9):3124-3131. PubMed ID: 32920717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of Antidrug Antibody Formation to Infliximab in Crohn's Patients With Prior Failure of Thiopurines.
    Bar-Yoseph H; Waterman M; Almog R; Billiet T; Vermeire S; Ungar B; Yanai H; Dotan I; Ben-Horin S; Chowers Y
    Clin Gastroenterol Hepatol; 2017 Jan; 15(1):69-75. PubMed ID: 27404966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcomes of patients with Crohn's disease who received infliximab or adalimumab as the first-line biologics.
    Inokuchi T; Takahashi S; Hiraoka S; Toyokawa T; Takagi S; Takemoto K; Miyaike J; Fujimoto T; Higashi R; Morito Y; Nawa T; Suzuki S; Nishimura M; Inoue M; Kato J; Okada H
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1329-1336. PubMed ID: 30724387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse Events of Thiopurine Therapy in Pediatric Inflammatory Bowel Disease and Correlations with Metabolites: A Cohort Study.
    Jagt JZ; Pothof CD; Buiter HJC; van Limbergen JE; van Wijk MP; Benninga MA; de Boer NKH; de Meij TGJ
    Dig Dis Sci; 2022 Jan; 67(1):241-251. PubMed ID: 33532972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiopurines and their optimization during infliximab induction and maintenance: A retrospective study in Crohn's disease.
    Luber RP; Dawson L; Munari S; Kariyawasam VC; Martin C; Gibson PR; Sparrow MP; Ward MG
    J Gastroenterol Hepatol; 2021 Apr; 36(4):990-998. PubMed ID: 32881046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.
    Chande N; Townsend CM; Parker CE; MacDonald JK
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD000545. PubMed ID: 27783843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Retrospective Claims Database Study on Drug Utilization in Japanese Patients with Crohn's Disease Treated with Adalimumab or Infliximab.
    Yokoyama K; Yamazaki K; Katafuchi M; Ferchichi S
    Adv Ther; 2016 Nov; 33(11):1947-1963. PubMed ID: 27664107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model.
    Siegel CA; Finlayson SR; Sands BE; Tosteson AN
    Clin Gastroenterol Hepatol; 2012 Jan; 10(1):46-51. PubMed ID: 21963958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease.
    Benmassaoud A; Al-Taweel T; Sasson MS; Moza D; Strohl M; Kopylov U; Paradis-Surprenant L; Almaimani M; Bitton A; Afif W; Lakatos PL; Bessissow T
    Dig Dis Sci; 2018 May; 63(5):1302-1310. PubMed ID: 29243105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.
    Chande N; Tsoulis DJ; MacDonald JK
    Cochrane Database Syst Rev; 2013 Apr; (4):CD000545. PubMed ID: 23633304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose infliximab therapy in Crohn's disease: clinical experience, safety, and efficacy.
    Hendler SA; Cohen BL; Colombel JF; Sands BE; Mayer L; Agarwal S
    J Crohns Colitis; 2015 Mar; 9(3):266-75. PubMed ID: 25540149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy and safety of infliximab in the treatment of pediatirc Crohn's disease].
    Xu X; Xiao Y; Yu Y; Li J; Huang YQ; Cao W; Hu H; Zhang T; Xu CD; Wang XQ
    Zhonghua Er Ke Za Zhi; 2021 Jul; 59(7):557-562. PubMed ID: 34405637
    [No Abstract]   [Full Text] [Related]  

  • 13. Is It Useful to Monitor Thiopurine Metabolites in Pediatric Patients with Crohn's Disease on Combination Therapy? A Multicenter Prospective Observational Study.
    Pospisilova K; Siroka J; Karaskova E; Hradsky O; Lerchova T; Zarubova K; Copova I; Gonsorcikova L; Velganova-Veghova M; Francova I; Urbanek L; Geryk M; Mihal V; Bronsky J
    Paediatr Drugs; 2021 Mar; 23(2):183-194. PubMed ID: 33709340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NUDT15 intermediate metabolisers are associated with lower loss of response in paediatric Crohn's disease patients treated by combination treatment with infliximab and azathioprine.
    Kim ES; Choi S; Choi SY; Park JH; Choe BH; Lee SY; Kim MJ; Choe YH; Kang B
    Aliment Pharmacol Ther; 2022 Apr; 55(8):1008-1015. PubMed ID: 35032047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Neutrophil-lymphocyte ratio at 14th week predicts loss of response to 52-week infliximab therapy in patients with Crohn's disease].
    Qian G; Hongxia D; Jin LI
    Nan Fang Yi Ke Da Xue Xue Bao; 2020 Apr; 40(4):453-458. PubMed ID: 32895126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab for pediatric patients with Crohn's disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan.
    Tajiri H; Motoya S; Kinjo F; Maemoto A; Matsumoto T; Sato N; Yamada H; Nagano M; Susuta Y; Ozaki K; Kondo K; Hibi T
    PLoS One; 2018; 13(8):e0201956. PubMed ID: 30114224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of concomitant elemental diet therapy in scheduled infliximab therapy in patients with Crohn's disease to prevent loss of response.
    Kamata N; Oshitani N; Watanabe K; Watanabe K; Hosomi S; Noguchi A; Yukawa T; Yamagami H; Shiba M; Tanigawa T; Watanabe T; Tominaga K; Fujiwara Y; Arakawa T
    Dig Dis Sci; 2015 May; 60(5):1382-8. PubMed ID: 25532505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease.
    Roblin X; Duru G; Williet N; Del Tedesco E; Cuilleron M; Jarlot C; Phelip JM; Boschetti G; Flourié B; Nancey S; Peyrin-Biroulet L; Paul S
    Inflamm Bowel Dis; 2017 Jan; 23(1):126-132. PubMed ID: 28002129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease.
    Yang E; Panaccione N; Whitmire N; Dulai PS; Vande Casteele N; Singh S; Boland BS; Collins A; Sandborn WJ; Panaccione R; Battat R
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1031-1038. PubMed ID: 32329532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with infliximab for pediatric Crohn's disease: Nationwide survey of Japan.
    Hosoi K; Ohtsuka Y; Fujii T; Kudo T; Matsunaga N; Tomomasa T; Tajiri H; Kunisaki R; Ishige T; Yamada H; Arai K; Yoden A; Ushijima K; Aomatsu T; Nagata S; Uchida K; Takeuchi K; Shimizu T
    J Gastroenterol Hepatol; 2017 Jan; 32(1):114-119. PubMed ID: 27478130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.